Intra-Cellular Therapies, Inc.

Period: Aug 11, 2014 to Apr 28, 2017

Lead Plaintiff Deadline: Jul 11, 2017

Summary of Case:

A securities class action has been filed against Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) on behalf of purchasers of Intra-Cellular securities from August 12, 2014 through April 28, 2017.  This case has been filed in the USDC - E.D.N.Y.

The Complaint alleges that throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (1) findings related to toxicity in animals treated with lumateperone (ITI-007) were observed; (2) these findings posed an additional safety concern regarding lumateperone; and (3) as a result, Intra-Cellular Therapies's public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

If you purchased this company's shares during the Class Period and suffered a loss or for further information about the case, please review the links below.

Join This Action